Connor Frey

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 8

Top Topics

Irritable Bowel Syndrome

Magnetic Nanoparticles

Myasthenia Gravis

Top Venues

Antibodies (Basel, Switzerland)

European journal of haematology

Analytical methods : advancing methods and applications

This page only lists publications with an associated author ORCID identifier.

Publications

Connor Frey, Mahyar Etminan
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database. Antibodies (Basel, Switzerland) 13 (3) (2024)
Connor Frey, Mahyar Etminan
Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. Antibodies (Basel, Switzerland) 13 (3) (2024)
Connor Frey, Mahyar Etminan
Immune-Related Adverse Events Associated with Atezolizumab: Insights from Real-World Pharmacovigilance Data. Antibodies (Basel, Switzerland) 13 (3) (2024)
Connor Frey, Hannah M Cherniawsky, Mahyar Etminan
Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review. European journal of haematology 113 (1) (2024)
Connor Frey, Hannah M Cherniawsky, Mahyar Etminan
Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review. European journal of haematology (2024)
Connor Frey, Mahyar Etminan
Adverse Events of PD-1, PD-L1, CTLA-4, and LAG-3 Immune Checkpoint Inhibitors: An Analysis of the FDA Adverse Events Database. Antibodies (Basel, Switzerland) 13 (3) (2024)
Connor Frey, Hannah M Cherniawsky, Mahyar Etminan
Ocular adverse events following CAR-T cell therapy: A pharmacovigilance study and systematic review. European journal of haematology 113 (1) (2024)
Kenneth Ku, Connor Frey, Maor Arad, Golfam Ghafourifar
Development of novel enzyme immobilization methods employing formaldehyde or triethoxysilylbutyraldehyde to fabricate immobilized enzyme microreactors for peptide mapping. Analytical methods : advancing methods and applications 14 (41) (2022)